CURRICULUM VITAE
Sabarinath Venniyil Radhakrishnan MD
Sabarinath Venniyil Radhakrishnan MD
Assistant Professor
Department of Medicine
Division of Hematology and Oncology - Medicine
Department of Medicine
Division of Hematology and Oncology - Medicine
OFFICE ADDRESS: |
Froedtert East Clinics |
9200 W Wisconsin Ave |
Milwaukee, WI 53226 |
EDUCATION: |
09/1996 - 01/2001 M.B.B.S, University of Kerala, Trivandrum, India |
03/2001 - 03/2002 Internship, University of Kerala, Trivandrum, India |
03/2003 - 03/2006 MD General Medicine, University of Kerala, Trivandrum, India |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
07/2010 - 06/2013 Internal Medicine Residency, Department of Internal Medicine, Louisiana State University Health Sciences Center
Shreveport |
07/2013 - 06/2017 Hematology/Oncology Fellowship, Division of Hematology & Oncology, Huntsman Cancer Institute/University of Utah |
FACULTY APPOINTMENTS: |
08/2017 - 07/2019 Visiting Instructor, Hematology & Hematological Malignancies, University of Utah, UT |
08/2019 - 06/2020 Assistant Professor, Hematology & Hematological Malignancies, University of Utah, UT |
07/2021 - Present Assistant Professor, Medicine, Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI 53226 |
SPECIALTY BOARDS AND CERTIFICATION: |
Board Certified | Issue Date | Expiration |
Internal Medicine (ABIM) | 10/2013 | None |
Medical Oncology (ABIM) | 12/2016 | None |
Hematology (ABIM) | 12/2016 | None |
Licensure | Number | Issue Date | Expiration |
Travancore-Cochin Medical Council (India) | 2002 | None | |
Medical License in Louisiana | 2010 | 2013 | |
Medical License in Utah | 2013 | None | |
AWARDS AND HONORS: |
2012 Abstract Achievement Award, American Society of Hematology (ASH) |
2015 Joseph M Quagliana MD & Paula Quagliana Fellow Research Award, University of Utah |
2017 - 2019 Pfizer Fellowship Award in Immuno-oncology Research, American Association for Cancer Research (AACR) |
2022 - 2024 New Investigator Award , American Society for Transplantation and Cellular Therapy (ASTCT) |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
National |
A novel CAR T cell therapy for multiple myeloma., Immunology, Inflammation & Infectious Disease Summer symposium, Park City, Utah,, 08/2017 |
International |
A high throughput process for generation and characterization of functional chimeric antigen receptors against novel targets, University of Wurzburg, 03/2017 |
PRESENTATIONS AND ABSTRACTS: |
06/2011 Mediation of LA-4 lung epithelial cell injury by allo reactive donor T cells. American Society for Clinical Oncology (ASCO), annual meeting, Chicago, June 2011 |
02/2012 The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases the Severity of Acute Lung Injury after Allogeneic Hematopoietic Cell Transplantation. American Society of Hematology (ASH) annual meeting, Atlanta, December 2012 |
02/2013 Azithromycin induces the expansion of regulatory T cells and diminishes allo reactive T cell proliferation in vitro and in vivo. American Society for Blood and Marrow Transplantation (ASBMT) annual meeting, Salt Lake City, February 2013 |
03/2017 Rapid Process for the Generation of Functional Chimeric Antigen Receptors Against Novel Targets. European Society for Blood and Marrow Transplantation (EBMT) annual meeting, Marseilles, March 2017 |
04/2017 A high-throughput process for the development and characterization of chimeric antigen receptors (CARs). American Association of Cancer Research (AACR) annual meeting, Washington DC, April 2017. |
09/2017 A Novel High Throughput Process for Generation and Characterization of Chimeric Antigen Receptor (CAR) T Cells. Society of Hematologic Oncology (SOHO) annual meeting, Houston, September 2017 |
12/2017 Chimeric Antigen Receptor (CAR) T Cells Specific for CD229: A Potentially Curative Approach for Multiple Myeloma. American Society of Hematology (ASH) annual meeting, Atlanta, December 2017 |
12/2018 Dimethyl Oxalyl Glycine a Prolyl Hydroxylase Inhibitor Decreases Early Gastrointestinal Gvhd Via Two Independent Pathways of Apoptosis after Allogeneic Hematopoietic Cell Transplantation. American Society of Hematology (ASH) annual meeting, San Diego, December 2018 |
04/2020 CD229-targeted CAR T cell therapy for the treatment of B cell lymphoma. American Association of Cancer Research (AACR) annual meeting,Philadelphia, April 2020 |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. The role of surface molecule CD229 in Multiple Myeloma.
Olson M, Radhakrishnan SV, Luetkens T, Atanackovic D. Clin Immunol. 2018 Oct 13. pii: S1521-6616
|
2. Elotuzumab as a Novel Anti-Myeloma Immunotherapy.
Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D. Human Vaccines and Immunotherapeutics. Volume 13, issue 8, May 2017
|
3. Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma.
Atanackovic D, Luetkens T, Radhakrishnan S, Kroeger N, Current Cancer Drug Targets. 2017;17(9):839-845
|
4. Novel anti-myeloma immunotherapies targeting the SLAM family of receptors. Radhakrishnan SV, Bhardwaj N, Luetkens T, Atanackovic D. Oncoimmunology. 2017 Mar 28;6(5):e1308618 |
5. Current Strategies for the Immunotherapy of Multiple Myeloma.
Luetkens T, Yousef S, Radhakrishnan SV, Atanackovic D. Oncology (Williston Park). 2017 Jan 15;31(1).
|
6. Immunotherapies targeting CD38 in Multiple Myeloma.
Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T. Oncoimmunology. 2016 Aug 5;5(11).
|
7. Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.
Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T. Br J Haematol 2016 Mar 20;172(5):685-98
|
8. A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population.
Radhakrishnan SV and Hildebrandt GC. Curr Hematol Malig Rep. 2015 Mar;10(1):8-17
|
Books, Chapters, and Reviews |
1. Chronic graft versus host disease: Clinical Manual of Blood and Bone Marrow Transplantation.
Radhakrishnan SV and Couriel DR, June 2017
|
2. Red cell destruction disorders: Hematology Board Review: Blueprint Study Guide and Q&A. Radhakrishnan SV and Parker CJ, May 2018 |
Non-Refereed Journal Publications/Original Papers |
1. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide.
Radhakrishnan SV, Luetkens T, Scherer SD, Davis P, Vander Mause ER , Olson M, Yousef S, Panse J, Abdiche Y, Li KD, Miles RR, Matsui W, Welm AL, Atanackovic D. Nat Commun. 2020 Feb 7;11(1):798.
|
2. The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation.
Palaniyandi S, Kumari R, Radhakrishnan SV, Strattan E, Hakim N, Munker M, Kesler MV, Hildebrandt GC. Transplantation. 2020 Jun 29.
|
3. A phase 1 study of intravenous busulfan as a conditioning regimen for Multiple Myeloma. Radhakrishnan SV, Boyer M, Sherwin CM, Zangari M, Tricot GJ. Cell Transplant. 2019 Dec;28(12):1624-1631. |
4. In Vivo Vaccination Effect in Multiple Myeloma Patients Treated with the Monoclonal Antibody Isatuximab.
Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens T. Leukemia. 2020 Jan;34(1):317-321.
|
5. Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/ NFKB/MAPK activation.
Templin J, Atanackovic D, Hasche D, Radhakrishnan SV, Luetkens T. Oncotarget. 2017 Jul 25;8(30):49253-49263
|
6. Pomalidomide as Consolidation Therapy after Salvage Autologous Stem Cell Transplant. Steinbach M, Luetkens T, Vinik K, Radhakrishnan SV , Atanackovic D. J J Bone Stem Res. 2016, 2(2): 015 |
7. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft versus host disease in a murine model of allogeneic hematopoietic cell transplantation. Radhakrishnan SV, Palaniyandi S, Mueller G, Miklos S, Hager M, Spacenko E, Karlsson FJ, Huber E, Kittan NA, Hildebrandt GC. Biol Blood Marrow Transplant. 2015 Jan;21(1):30-8. |
8. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage.
Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, Radhakrishnan SV, Hanke K, Schmitt-Graeff A, Freudenberg M, von Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmah O, Schönle A, Martin SF, Mertelsmann R, Duyster J, Finke J, Prinz M, Henneke P, Häcker H, Hildebrandt GC, Häcker G, Zeiser R. Nat Med. 2014 Jun;20(6):648-54.
|
9. Murine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latent infection.
Palaniyandi S, Radhakrishnan SV, Karlsson FJ, Stokes KY, Kittan N, Huber E, Hildebrandt GC. PLoS One. 2013 Apr 15;8(4).
|
10. Beneficiary Effect of Autologous Hematopoietic Cell Transplantation in Idiopathic Ulcerative Dermatitis C57BL/6 Mice.
Palaniyandi S, Huber E, Radhakrishnan SV, Orchard EA, Hildebrandt GC. J Bone Marrow Res. 2: 139
|
Patents |
1. CD229 CAR T Cells and Methods of Use Thereof.
Luetkens T, Atanackovic D, Radhakrishnan SV (Published). Patent No.WO2018017708A1.
01/25/2018
|
